Connect with us


“Huge relief” as threat to children’s medical cannabis is resolved



Hannah Deacon (pictured with her son Alfie) has spent weeks calling on the government to find a solution

Families have welcomed the news that the Dutch government will continue to supply life-saving cannabis products for UK patients for the next six months. 

The Dutch government has confirmed it will continue to supply Bedrocan oil for UK prescriptions until 1 July 2021.

In a letter the Department of Health and Social Care (DHSC) said it was ‘committed’ to using the coming months to find a ‘permanent solution’.

Dozens of patients, including children with severe epilepsy, who are prescribed the oils in the UK but can only obtain their prescription through the Transvaal pharmacy in the Netherlands, were left without access to the medication after the UK left the EU. 

Families were given just two weeks’ notice that prescriptions issued in the UK ‘can no longer be lawfully dispensed in an EU Member State’ following the end of the Brexit transition period on 31 December 2020. 

Hannah Deacon, whose son Alfie, six, is prescribed Bedrolite on the NHS, has been calling on the UK government for weeks to find a solution.

“It’s a huge relief for our family and all those affected that this short-term agreement has been reached,” she said.

“Now our attention needs to turn to finding a long-term solution and resolving the ongoing issues facing families in the UK, who are faced with the daily struggle of attempting to find the money to privately fund private prescriptions for their child’s epilepsy. 

“I am very fortunate to have an NHS prescription for Alfie, but I will continue to fight alongside these families until we have access for all patients.”

Campaign group End Our Pain, which represents 40 families of children and young people who rely on medical cannabis, also welcomed the news.

“We welcome the news that the imminent threat to the ongoing supply of Bedrocan products from Holland, which are vital for the health and wellbeing of many families with children affected by intractable epilepsy, has been resolved in the short term,” it said in a statement on social media.

“We understand that the Dutch Government has been understanding and accommodating and thank them for that. We also thank UK Health Minister Jo Churchill for her role together with the officials involved both in the DHSC, Number 10 and the Home Office.”

However, the group highlighted the need for an urgent solution to the barriers in accessing cannabis medicines in the UK.

With only a handful of prescriptions issued on the NHS, parents are still faced with raising thousands to fund them privately each month.

“We make another urgent and insistent plea to all those involved in the UK Government to solve the remaining crisis, funding both for Bedrocan products and other whole plant extract medical cannabis that our families rely on,” it continued.

“Families have found whole plant extract medical cannabis is life-transforming and indeed lifesaving for their children, but they are still having to raise up to £2,000 a month to pay for a medicine that is legal here. These families are at financial and emotional breaking point.”

End Our Pain is calling for an emergency fund to be set up to help families pay for these prescriptions until they are able to access them on the NHS.

“Our view is that the blocks to prescribing on the NHS need to be removed, but this will take time and our families haven’t got time. They are running out of money and their fundraising options have been all but totally shut down since Covid struck,” it added.

“For that reason, we are continuing to call for the establishment of an emergency fund which can be used to help the families pay for the private prescriptions until the NHS starts prescribing.

“This is the only way that the families can be helped immediately.”


Weekend digest: Six big stories from the cannabis world you might have missed



Another week, another rollercoaster in the fast-moving world of cannabis.

At Cannabis Health, our in depth coverage of the ongoing growth of cannabis as a medical and wellness product continues

Meanwhile, over at Cannabis Wealth, we’ve been following all the big industry and policy news in a week which has seen some important developments..

Been busy and want to get caught up in a hurry?

Here are the six things you need to read to stay in the loop this week.

1. Products pulled from shelves

Two batches of medical cannabis products have been recalled by regulators as investigations are carried out, following reports they may be contaminated with mould.

Medical cannabis pharmacy, Dispensary Green and the Medicines and Healthcare products Regulatory Agency (MHRA) have issued a ‘precautionary’ product recall since being made aware of ‘defects’ in patient’s medication.

Concerns were initially raised after a number of medical cannabis patients spotted what they believed to be mould spores in their prescriptions.

Full story here.

2. NFL turns to medical cannabis

The National Football League (NFL) in America is providing $1 million in funding for research into pain management and cannabinoids.

The NFL is funding research into medical cannabis.

The pain management committee of the NFL and the NFL Players Association announced it would stump up the funding on Tuesday 8 June.

According to the organisation’s news platform, the move is the next step in a shifting attitude towards players who use medicinal cannabis to manage pain from injuries.

You can read more here.

3. More medical cannabis evidence

Researchers have found that the cannabinoids CBD and CBG, when used in combination, are beneficial for treating inflammation in the lungs.

Scientists at King’s College London, working in collaboration with Sativa Wellness Group have published the first results from a study into the impact of cannabinoids on respiratory diseases.

It aimed to investigate the anti-inflammatory effects of the two non-psychotropic cannabinoids alone and in combination, in a model of pulmonary inflammation.

Full details here.

4. Germany to vote for reform?

Germany’s national election on September 26 could be a landmark moment for Europe’s cannabis industry.

As Chancellor Angela Merkel prepares to leave the stage, the European Union’s most influential country looks destined for a political shakeup.

Annalena Baerbock could become Germany’s first pro-drug reform Chancellor.

It could mark a huge moment for the cannabis industry as Germany’s parliament might swing in favour of legislation.

Here’s everything you need to know about it.

5. Adapt or fail

The pro-drug reform lobby must accept it has failed and change to push its agenda ahead, leading experts have warned.

Speaking at a Global Cannabis Intelligence event about the state of advocacy in the UK, three leading policy advocates set out how they think greater access can be achieved.

The discussion comes week after the 50-year anniversary of the passage of the The Misuse of Drugs Act.

Read the full story here.

6. Isle of Man steps up

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3m a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

Full details here.

Continue Reading


New tracking app launches for UK medical cannabis patients

Through the app patients will be able to monitor their own symptoms and medication usage



The free health monitoring app is already being used elsewhere in the world.

UK medical cannabis suppliers Grow Pharma have teamed up with an Australian tech firm to launch a new app for patients.

The partnership with OnTracka will see them launch Calyx, a free health monitoring app already being used elsewhere in the world.

Users will be able to monitor their own symptoms and medication usage, speak securely with their doctor and contribute to gathering evidence about the use of medical cannabis.

The app will also be available in Ireland and the Channel Islands after successful launches in Australia, the US and South America.

Users will be able to monitor their own symptoms and medication usage

Pierre Van Weperen, CEO of Grow Pharma said: “Grow Pharma is currently fulfilling around a third of all prescriptions for the UK’s medicinal cannabis patients.

“Our prominent role gives us a significant advantage to building data insights into how patients are managing their health.

“This is integral to pave the way towards increasing access for patients in the UK through providing doctors with confidence around the safety and efficacy of these products.

“Using the app will generate important insights to provide real-time evidence to doctors and regulators.”

Grow Pharma hopes the app will help ‘rapidly accelerate an understanding of the safety, quality, and efficacy’ of medical cannabis.

Insights gained via the app will ‘advance the industry forward in the service of patients, shaping future legislation and policy based on patient experiences’ by providing real-world data to regulators.

Grow is in the process of raising £6 million worth of capital via a private funding round expect to be completed later this month.

Continue Reading


Isle of Man launches medical cannabis export sector

The Isle of Man is open for business to the medical cannabis industry.



The move could 250 new jobs and generate £3 million a year for the island

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.

Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.

“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.

The Isle of Man wants to be a major player in Europe’s growing medical cannabis industry.

“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”

The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.

The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.

Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.

‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.

“What we now have will ensure that all stakeholders will be competent, crime free and capable of building a sector that is safe, trusted and efficient.

“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.

“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.

“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.

“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”

Continue Reading